Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Placebo-controlled Trial of Eicosapentaenoic Acid (EPA) and Antioxidant Supplementation in the Treatment of Schizophrenia and Related Disorders

NCT00419146 is registered in ClinicalTrials.gov with University Hospital, Aker as lead sponsor.

NCT NCT00419146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00419146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Placebo-controlled Trial of Eicosapentaenoic Acid (EPA) and Antioxidant Supplementation in the Treatment of Schizophrenia and Related Disorders
Lead sponsor
University Hospital, Aker
Phase
Phase 2/3
Overall status
Completed
Start date
September 30, 2001
Completion date
April 30, 2004
Enrollment
99 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psychotic disorders, schizoaffective disorder, schizophrenia, schizophreniform disorders